Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 2

Conditions: Central Retinal Vein Occlusion

Treatments: Drug: Bevasizumab; Drug: Triamcinolone Acetonide

Study type: Interventional

Funder types: Other

Identifiers

NCT01178697

8886

Details and patient eligibility

About

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recent onset (less than 3 months) central retinal vein occlusion

Exclusion criteria

• Any previous intervention

Trial design

0 participants in 2 patient groups

Intravitreal triamcinolone

Active Comparator group

Treatment:

Drug: Triamcinolone Acetonide

Intravitreal bevasizumab

Active Comparator group

Treatment:

Drug: Bevasizumab